Advertisement

Topics

AstraZeneca to partner with Merck on cancer drug in $8.5B pact

06:21 EDT 28 Jul 2017 | SmartBrief

AstraZeneca's Lynparza, or olaparib, for ovarian cancer will be co-developed and co-commercialized by Merck in a global deal  -More

Original Article: AstraZeneca to partner with Merck on cancer drug in $8.5B pact

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca to partner with Merck on cancer drug in $8.5B pact"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...